GlassScriptPhysician profile
Naeem Rahman
NPI 1366536245
$8,772.81
in general payments reported to CMS, 2019-2025
31 companies · $3,324 in 2025
The $3,324 reported for 2025 was more than what 88% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $4,038 · 2021: $489 · 2022: $67.26 · 2023: $94.71 · 2024: $357 · 2025: $3,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,783 · Food and Beverage: $993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,783.00 |
| Food and Beverage | $992.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,800.17 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $2,967.10 | 2019-2025 | Adstiladrin |
| Boston Scientific Corporation | $397.08 | 2021-2025 | Spaceoar System, Rezum Generator, Dakota |
| Urogen Pharma, INC. | $362.77 | 2021-2024 | |
| Pfizer INC. | $173.24 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.97 | 2019-2025 | |
| Astellas Pharma US INC | $107.03 | 2019-2020 | |
| Medtronic USA, INC. | $93.87 | 2019-2020 | |
| Cook Medical LLC | $78.84 | 2019 | |
| Antares Pharma, INC. | $75.16 | 2020-2021 | |
| Laborie Medical Technologies Corp. | $64.89 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Astrazeneca Pharmaceuticals LP | $59.63 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $46.19 | 2020-2021 | |
| Foundation Medicine, INC. | $44.30 | 2020-2021 | |
| Janssen Biotech, INC. | $43.90 | 2019-2025 | Erleada |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Civco Medical Instruments | $43.14 | 2025 | |
| Contura, INC. | $34.44 | 2020 | |
| Endo Pharmaceuticals INC. | $33.74 | 2019 | |
| Myovant Sciences INC. | $29.30 | 2021-2022 | |
| C. R. Bard, INC. & Subsidiaries | $24.64 | 2019 | |
| Allergan, INC. | $21.33 | 2021 | |
| Sumitomo Pharma America, INC. | $20.10 | 2023 | Orgovyx |
| Immunitybio, INC. | $19.63 | 2024 | |
| Axogen | $19.00 | 2025 | |
| Novocure INC. | $17.59 | 2025 | Optune Lua (Novottf-200t) |
| Glaxosmithkline, LLC. | $16.06 | 2024 | Nucala |
| Telix Pharmaceuticals | $15.61 | 2025 | Illuccix |
| Medtronic, INC. | $14.83 | 2021 | |
| Qol Medical, LLC | $14.21 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.17 | 2021 | |
| Rochester Medical Corporation | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naeem Rahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.